+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ceritinib"

Ceritinib Capsules Market by End User (Hospitals, Retail Pharmacies, Specialty Clinics), Line of Therapy (First-Line, Second-Line), Distribution Channel - Global Forecast 2025-2030 - Product Thumbnail Image

Ceritinib Capsules Market by End User (Hospitals, Retail Pharmacies, Specialty Clinics), Line of Therapy (First-Line, Second-Line), Distribution Channel - Global Forecast 2025-2030

  • Report
  • August 2025
  • 185 Pages
  • Global
From
Ceritinib API Market by Indication (Anaplastic Large Cell Lymphoma, Non Small Cell Lung Cancer Alk Positive), Line Of Therapy (First Line, Second Line, Third Line And Beyond), End User, Distribution Channel, Payer Type, Strength - Global Forecast 2025-2030 - Product Thumbnail Image

Ceritinib API Market by Indication (Anaplastic Large Cell Lymphoma, Non Small Cell Lung Cancer Alk Positive), Line Of Therapy (First Line, Second Line, Third Line And Beyond), End User, Distribution Channel, Payer Type, Strength - Global Forecast 2025-2030

  • Report
  • August 2025
  • 193 Pages
  • Global
From
Oncogene Inhibitor Global Market Report 2025 - Product Thumbnail Image

Oncogene Inhibitor Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

ALK Positive Non-Small Cell Lung Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • June 2024
  • 200 Pages
  • Global
From
Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • November 2023
  • 630 Pages
  • Global
From
Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030 - Product Thumbnail Image

Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • November 2023
  • 306 Pages
  • Global
From
Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy), By Regional Outlook and Forecast, 2023 - 2030 - Product Thumbnail Image

Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy), By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • July 2023
  • 290 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Ceritinib is an oncology drug used to treat non-small cell lung cancer (NSCLC). It is a type of tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Ceritinib is approved for the treatment of metastatic NSCLC in patients whose tumors have a specific genetic mutation known as ALK-positive. It is also approved for the treatment of NSCLC in patients who have progressed after treatment with crizotinib, another TKI. Ceritinib is available in tablet form and is taken orally once daily. Common side effects include nausea, vomiting, diarrhea, fatigue, and decreased appetite. More serious side effects may include liver damage, heart problems, and lung inflammation. Ceritinib is marketed by Novartis, Daiichi Sankyo, and Eisai. Show Less Read more